BackgroundRecent studies suggest certain antiretroviral therapy (ART) drugs are associated with increases in cardiovascular disease.PurposeWe performed a systematic review and meta-analysis to summarize the available evidence, with the goal of elucidating whether specific ART drugs are associated with an increased risk of myocardial infarction (MI).Data SourcesWe searched Medline, Web of Science, the Cochrane Library, and abstract archives from the Conference on Retroviruses and Opportunistic Infections and International AIDS Society up to June 2011 to identify published articles and abstracts.Study SelectionEligible studies were comparative and included MI, strokes, or other cardiovascular events as outcomes.Data ExtractionEligibility screening, data extraction, and quality assessment were performed independently by two investigators.Data SynthesisRandom effects methods and Fisher’s combined probability test were used to summarize evidence.FindingsTwenty-seven studies met inclusion criteria, with 8 contributing to a formal meta-analysis. Findings based on two observational studies indicated an increase in risk of MI for patients recently exposed (usually defined as within last 6 months) to abacavir (RR 1.92, 95% CI 1.51–2.42) and protease inhibitors (PI) (RR 2.13, 95% CI 1.06–4.28). Our analysis also suggested an increased risk associated with each additional year of exposure to indinavir (RR 1.11, 95% CI 1.05–1.17) and lopinavir (RR 1.22, 95% CI 1.01–1.47). Our findings of increased cardiovascular risk from abacavir and PIs were in contrast to four published meta-analyses based on secondary analyses of randomized controlled trials, which found no increased risk from cardiovascular disease.ConclusionAlthough observational studies implicated specific drugs, the evidence is mixed. Further, meta-analyses of randomized trials did not find increased risk from abacavir and PIs. Our findings that implicate specific ARTs in the observational setting provide sufficient evidence to warrant further investigation of this relationship in studies designed for that purpose.

Background Foreign aid for health has increased substantially in the past two decades. However, there is limited information on the relation between the distribution of foreign aid for health and the actual burden of disease in diff erent diseases and age groups, particularly children. We examined the association between disease-specifi c foreign aid for children (FACH) and burden of disease. Methods Burden of disease data including estimates of disability adjusted life years (DALYs) were derived from the WHO Global Health Estimates resource for 2000-11. Children 0-5 years of age in sub-Saharan African countries were examined and the number of DALYs lost for the top 15 diseases calculated. Data for foreign aid were derived from the AidData dataset, which includes descriptions of all foreign aid donations. We constructed an instrument that searched the text of each description for words indicative of a certain disease, such as "malaria" or "bed-net", and designated child or infant in the age category. Findings Overall, the amount of FACH increased substantially during the period 1996-2009, from US$3•5 billion in 1996 to US$13•5 billion in 2009. The relation between the burden of disease and the amount of disease-specifi c FACH was mixed. For example, diarrhoeal diseases were responsible for 19% of DALYs lost in 2009, and were targeted with 21% of FACH. By contrast, the amount of FACH targeted towards HIV in 2009 (5•5%) was much more than the that of lost DALYs caused by HIV (23%). Pneumonia, however, was responsible for the most DALYs lost in 2009 (29%) yet received only 0•6% of all FACH. Interpretation Our fi ndings suggest that the relation between the distribution of foreign aid for child health and burden of disease in sub-Saharan African countries is mixed. Further work is needed to analyse present distribution patterns of foreign aid for child health and to advise future distribution Funding None.